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Membrane insertion and 
secretion of the Engrailed-2 (EN2) 
transcription factor by prostate 
cancer cells may induce antiviral 
activity in the stroma
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Engrailed-2 (EN2) is a homeodomain-containing transcription factor that has roles in boundary 
formation and neural guidance in early development, but which is also expressed in a range of cancers. 
In addition to transcriptional regulation, it is secreted by cells and taken up by others through a 
mechanism that is yet to be fully elucidated. In this study, the distribution of EN2 protein in cells was 
evaluated using immunofluorescence with a set of antibodies raised against overlapping epitopes 
across the protein, and through the use of an EN2-GFP construct. MX2 expression in primary prostate 
tumors was evaluated using immunohistochemistry. We showed that EN2 protein is present in the cell 
membrane and within microvesicles that can be secreted from the cell and taken up by others. When 
taken up by normal cells from the stroma EN2 induces the expression of MX2 (MxB), a protein that has 
a key role in the innate immune response to viruses. Our findings indicate that EN2 secretion by tumors 
may be a means of preventing viral-mediated immune invasion of tissue immediately adjacent to the 
tumor.
Engrailed is a homeodomain-containing transcription factor originally identified through the effects of an inac-
tivating mutation in Drosophila that resulted in a failure of the border between the anterior and posterior wing 
compartments1. The human genome encodes 2 homologues of this gene, Engrailed-1 and Engrailed-2 (EN2), 
which have similar functions in early development2, although of the two EN2 has been more extensively charac-
terized3. Both EN1 and EN2 have a role in determining the midbrain/hindbrain border in vertebrates4,5, and their 
expression is required subsequently for development and continued survival of the mesencephalic dopaminergic 
neurons6–8.
Engrailed proteins primarily function as transcriptional repressors through an interaction with the 
co-repressor protein groucho9, although they have also been shown to regulate translation through binding to the 
eukaryotic translation initiation factor 4E10. In addition, there is evidence that EN2 can be secreted from cells in a 
process that is dependent on a peptide sequence within the DNA-binding homeodomain region11–14, and that in 
the developing brain this gives rise to an extracellular gradient of EN2 protein that can be taken up by temporal 
retina and nasal axons resulting in attraction and repulsion, respectively15. These effects on axonal migration 
appear to be mediated at the level of translational regulation exerted by the internalized EN2 protein15.
In addition to a role in neural development, early studies also indicated that EN2 had an oncogenic function in 
breast cancer cells as its forced expression in non-tumorigenic mammary cell lines resulted in a number of malig-
nant characteristics including a loss of cell-to-cell contact and a failure to differentiate in response to lactogenic 
hormones16. More recently it has been shown that EN2 is expressed in a number of other tumor types, including 
those of the prostate17–19 and bladder20. The presence of EN2 protein in the urine of prostate and bladder cancer 
patients has been shown to have both diagnostic and prognostic value as the concentration of urinary EN2 corre-
lates with both tumor size and grade17–21.
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Despite the highly unusual properties of EN2 and its importance both in development and in cancer, there 
is in fact still relatively little known of the underlying molecular mechanisms. For example, it is unclear whether 
EN2 is actually present in the membrane of cells, or whether it is secreted or taken up by an active mechanism. 
There is also no direct evidence that it can be taken up by neighboring cells, or that in doing so it alters the behav-
ior of these cells. In this study, we show that EN2 is indeed present in the membrane of cancer cells and that it is 
secreted through an active mechanism that is dependent on vesicle formation, and that cells that take up exog-
enous EN2 protein undergo distinct changes in behavior that could profoundly influence tumor development 
through modification of the tumor microenvironment.
Methods
Cell culture. Human prostate adenocarcinoma PC-3 cells, human prostate carcinoma LnCaP and DU145 
cells, and human normal prostate stroma/fibroblast WPMY-1 cells were obtained from the American Type 
Culture Collection (ATCC) and cultured as previously described22. The human melanoma cell line SKMEL5 
(HTB-70) was obtained from the ATCC via LGC Standards Ltd and cultured according to ATCC protocols. 
The promyelocytic leukemia derived cell line HL60 was also obtained from the ATCC (via LGC Standards 
Ltd) and was cultured as previously described23. Growth conditions for all the cell lines used are presented in 
Supplementary Table 1.
Production of transient and stable GFP-EN2 clones. Plasmid transfections for forced expression of 
EN2 tagged with GFP were carried out following the manufacturer’s instructions using Lipofectamine® 2000 (Life 
Technologies, UK) for DU145 cells (6 μl of reagent per 1 μg of DNA) or ViaFect™ (Promega, UK) for the other 
cell lines, using the following reagent(μl):DNA(μg) ratios: PC3 (3:1), LnCaP (5:1), WPMY-1 (6:1), SKMEL-5 
(5:1). During transfection, cells were starved by reducing fetal bovine serum levels in fresh media from 10% to 
0.5%. Cell lines were transfected with DNA plasmid created using Myc-DDK tagged ORF clone of Homo sapiens 
EN2 as transfection ready DNA (accession number: NM_001427) and PrecisionShuttle mammalian vector with 
N-terminal mGFP (OriGene Technologies, USA), which enabled the expression of N-terminal GFP-tagged EN2. 
As a control, cell lines expressing GFP only were created in the same way using the PrecisionShuttle mammalian 
vector with N-terminal mGFP (OriGene Technologies, USA) alone.
EN2 silencing in PC3 GFP-EN2 stable cells. siRNA transfections were carried out using siPORTTM 
NeoFXTM transfection reagent (Invitrogen, UK) following the manufacturer’s protocol. Briefly, EN2 siRNA 
(4676; mRNA sequence accession number NM_001427.3, targeted exon 2, siRNA location 1110 bp) or 
negative control siRNA diluted in Optimem and siPORTTM NeoFXTM transfection reagent diluted in 
Optimem were mixed at 1:1 ratio, added to PC3 cells and EN2 protein detected 48 h after transfection using 
immunocytochemistry.
Quantitative real-time PCR (RT-qPCR). Total RNA was isolated using the RNeasy Plus Micro Kit 
(Qiagen, UK) followed by a two-step cDNA synthesis reaction using nanoScript Reverse Transcription kit 
(Primer design Ltd, UK) with annealing step preceding the extension step, all according to the manufactur-
er’s protocol. The mRNA expression of EN2, GAPDH and MX2 was quantified using the Stratagene Mx3005P 
qPCR system (Agilent Technologies, USA) with SYBR Green fluorescence technology with the following primer 
sequences: EN2 NM_001427 F: GAACCCGAACAAAGAGGACA and R: CGCTTGTTCTGGAACCAAAT, 
GAPDH NM_002046.5, F: GAACCCGAACAAAGAGGACA and R: CGCTTGTTCTGGAACCAAAT, and 
MX2 NM_002463: F: AAGCAGTATCGAGGCAAGGA and R: TCGTGCTCTGAACAGTTTGG. EN2 and MX2 
expressions were normalised to GAPDH using the ΔCt relative quantification method.
EN2 protein detection in cell lines. Immunocytochemistry was used to demonstrate the  presence of 
EN2 in cells. Cell lines were grown overnight in an 8-chambered polystyrene culture treated glass slides (BD 
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Figure 1. Engrailed-2 (EN2) expression in various cancer and normal derived cell lines. (A) qRT-PCR for EN2 
mRNA expression, normalised to expression of the GAPDH house-keeping gene (x1000000). (B) Fluorescent 
micrograph of cancer cells stained with an anti-EN2 antibody. EN2 staining is shown in green (FITC-labeled 
secondary antibody). Cell nuclei are stained red (propidium iodide), images were taken by confocal microscopy 
at x 40 magnification.
3Scientific RepoRts |          (2019) 9:5138  | https://doi.org/10.1038/s41598-019-41678-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
cells were incubated with 10% horse serum (Jackson ImmunoResearch, USA) for 20 minutes and further with 
anti-EN2 goat polyclonal IgG primary antibody (Abcam, UK) diluted 1:100 in PBS/1% BSA at room temperature 
for 2 hours or overnight at 4 °C. A ‘no primary antibody’ sample was included containing PBS/1% BSA alone for 
use as a negative control. After primary antibody incubation, the cells were washed three times with PBS and 
incubated with donkey anti-goat secondary antibody (Abcam, UK) at 1:200 in the dark for 45 minutes. After incu-
bation, cells were washed three times with PBS, chambers removed and slides mounted using propidium iodide 
(PI) Vectashield® mounting medium (Vector Laboratories, USA). The slides were imaged at X40 magnification 
Figure 2. EN2 peptide-specific antibody panel for antibody-drug conjugate. A panel of sheep antibodies 
that target 20 amino acid (aa) immunogens across the length of the EN2 protein were used for cell surface 
fluorescence staining (green) with propidium iodide nuclear staining (red), 10X confocal microscopy.
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using the Nikon A1M confocal microscope and NIS elements acquisition software (Nikon, UK). Images were 
processed with ImageJ.
EN2 staining using epitope-specific antibodies. A panel of 19 polyclonal sheep antibodies, Ab2 - Ab33 
(kindly provided by Bioventix, UK, as part of a collaborative project) (Supplementary Table 2), were made against 
peptides covering the whole length of the EN2 protein. Each peptide was 20 amino acids long and overlapped its 
neighboring peptides by 10 amino acids. These antibodies were generated in sheep using a nested peptide series 
conjugated to the metalloprotein, KLH. Immunocytochemical staining was performed as described above, except 
5% horse serum was used for blocking and donkey anti-sheep secondary antibody (Abcam, UK) at 1:10,000 dilu-
tion was used for visualisation.
time-lapse confocal microscopy. PC3 cells were seeded in a 4-chamber glass-bottom dish (MatTek, 
USA) and 24 hours later transfected with 0.5 μg of either GFP-EN2 or GFP (control) plasmids as described above. 
After further 24 h incubation, the media was changed to Gibco® FluoroBrite™ DMEM (Life Technologies, UK) 
in order to enhance the fluorescent signal. GFP fluorescence was detected using confocal microscopy. Time-lapse 
mode was selected and the areas to be imaged were chosen by focusing on the cells as well as labelling and setting 
the X/Y parameters. Images were set to be taken every 5 minutes over 24 hours. Fold difference in fluorescence 
from T0 was calculated and plotted over time.
EN2 direct co-culture assay. To investigate the intercellular transfer of EN2, stable PC3 LifeAct® (Ibidi, 
Germany) expressing clones were created as described above. F-actin was visualized in the cells to reveal the 
cytoskeleton without compromising cellular processes. These cells were then directly co-cultured with PC3 
EN2GFP (green fluorescence) or PC3 GFP cells in 6-well plates at half the normal density in DMEM culture 
media. Images were taken after 72 h using a fluorescence microscope at X20 or X40 magnification. The assay was 
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Figure 3. EN2 localisation confirmed using GFP-EN2 de novo expression. (A) qRT-PCR of GFP-EN2 
overexpression with 1μg plasmid DNA (left), these were analysed by fluorescence microscopy 48 h after 
transfection (right). (B) GFP-EN2 stably expressing cells treated with EN2 siRNA, negative scrambled siRNA 
or media only imaged at x20 magnification using a fluorescence microscope and probed with goat anti-EN2 
antibody, 48hrs after transfection. (C) PC3 cells transfected transiently and stably with GFP-EN2 plasmid DNA 
were then co-stained with wheat germ agglutinin membrane stain (red), these were imaged and analysed using 
the confocal microscopy software to show co-localisation (40X magnification), the arrows on the images depict 
the cell through which the measurement was taken.
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repeated and images taken after 96 h with addition of NucBlue® Live ReadyProbes® Reagent to demarcate the 
nucleus.
Immunohistochemistry. MX2 expression was investigated in prostate cancer and normal prostate using a 
3 µm-thick, formalin fixed, paraffin embedded tissue array (PR2085a, US Biomax, Rockville, MD, USA), with a 
rabbit polyclonal MX2 antibody (Abcam 224479) diluted 1:100 and the ABC detection method with peroxidase 
block (DakoCytomation). Antigen retrieval was performed using pH 6.0 citrate/EDTA buffer (DakoCytomation) 
and heating in a microwave for 23 minutes. DAB Peroxidase (HRP) Substrate Kit (Vector Laboratories) was used 
in the final detection step and images taken under a light microscope at × 40 magnification.
statistical analysis. Statistical analyses were performed using GraphPad-PRISM software (CA, USA) 
based on a minimum of two independent experiments using Student’s t-test for comparison between two groups. 
Significance was scored as: ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05.
Results
In order to understand more about the role of EN2 in cancer, we began by studying its expression in cells lines 
derived from tumors and normal tissue. RT-QPCR revealed that promyelocytic leukemia derived HL60, mel-
anoma derived SKMEL5, and the prostate cancer-derived cell lines DU145, PC3, and LNCaP, all express high 
levels of EN2, whilst WPMY-1 (a cell line derived from normal prostate fibroblasts) showed only very low levels of 
expression (Fig. 1A). Fluorescent confocal microscopy with an anti-EN2 antibody revealed that EN2 protein was 
present in the membrane of SKMEL5, PC3 and LnCaP cells (Fig. 1B). Given the apparent membrane expression 
of EN2, we sought to determine which parts of the EN2 protein were present on the outside of the cell, as this 
could help to identify potential target antigens for antibody therapy. In order to do this, a series of antibodies were 
raised in sheep using 20 amino acid peptides that overlapped each other by 10 amino acids, and which together 
covered the whole length of the EN2 protein. When the antibodies were used to stain PC3 cells that had not been 
treated to make the membrane permeable, only antibody 32 (Ab32), corresponding to the C-terminal most por-
tion of EN2, gave a strong signal compared to WPMY-1 cells that were used as a negative control (Fig. 2).
To further explore the cellular distribution of EN2 we made an EN2-green fluorescent protein (GFP) con-
struct, which produced GFP-EN2 mRNA and GFP-EN2 protein when transfected into cells (Fig. 3A). The iden-
tity of this protein was confirmed in the transfected cells through specific knockdown using an anti-EN2 siRNA 
(Fig. 3B). As with the endogenous EN2 protein, a significant proportion of GFP-EN2 was found to be present in 
the cell membrane upon confocal microscopy. GFP alone was only located in the cytoplasm (Fig. 3C).
Following the transfected cells over time revealed that GFP-EN2 transfected PC3 cells began to secrete 
GFP-EN2 protein in discrete bodies (Video). This behavior was not observed for LNCaP, WPMY-1, or SKMEL-5 
cells transfected with GFP-EN2, or in any of these cell types transfected with GFP alone (data not shown). The 
fluorescence was quantified over this time period, revealing that GFP-EN2 secretion from PC3 cells began shortly 
before a large spike in fluorescence (Fig. 4A, blue arrow). The imaging of single cells at higher magnification 
confirmed the production of GFP-EN2 containing bodies and the uptake of these bodies by other cells (Fig. 4B). 
We further assessed the mechanism of uptake of EN2 by co-culturing PC3 or WPMY-1 cells transfected with 
EN2-GFP with untransfected cells labelled using LifeAct (red). This indicated that EN2-GFP can indeed move 
PC3 GFP-EN2 
Secretion 






Figure 4. Microvesicle secretion of EN2 was only observed in PC-3 prostate cancer cells. (A) Stills of time-lapse 
video of transiently overexpressed GFP-EN2 in PC3 cancer cells (top) and the fold difference in fluorescence 
from T0 plotted over time (bottom). (B) Stills from a time-lapse video of PC3 cells transiently overexpressing 
EN2-GFP (green fluorescence), showing the formation of intracellular vesicles (1 second, red arrow), its 
uptake by a non-adherent cell (10 seconds, red arrow), and the subsequent adhesion and migration of that cell 
(14 seconds, red arrow).
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between cells, although this process appears to require cell to cell contact (Fig. 5A). Once internalized, the 
imported EN2-GFP protein is restricted to specific areas of the cell within the cytoplasm (Fig. 5B).
The secretion and uptake of EN2 protein suggests the possibility that normal prostate cells adjacent to pros-
tate tumour cells could be exposed to sufficiently high levels of EN2 to change their transcriptional states. To 
address this possibility, we exposed WMPY-1 cells, which are derived from non-malignant prostate fibroblast 
cells, to purified EN2 protein and used microarray to look for genes that show a stepwise increase or decrease 
in expression with increasing amounts of EN2 protein. This approach revealed only a single gene that showed 
such a dose-response relationship, MX dynamin-like GTPase2 (MX2, also known as MxB), which encodes a 
dynamin related protein24. The MX2 genomic region contains an EN2/PBX binding site within a intronic region 
(Fig. 6A), and qPCR analysis of WMPY-1 cells treated with EN2 protein revealed a 12-fold increase in transcrip-
tion stepwise over 4 logs of increasing protein concentration (Fig. 6B). Analysis of MX2 expression in primary 
prostate tumours, normal prostate tissue and normal tissue adjacent to tumours (NAT) revealed high levels of 
MX2 expression only in NAT (Fig. 6C). Correspondingly, immunohistochemical analysis of prostate tumours and 
normal prostate tissue revealed that MX2 protein is only present in the stroma surrounding prostate tumours and 
not in normal prostate tissue (Fig. 6D).
PC3 lifeact + PC3 GFP 
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Figure 5. EN2 co-culture assay. (A) PC3 EN2-GFP and GFP control stable cell lines (green) were co-cultured 
with either PC-3 or WPMY-1 stable LifeAct (red) cell lines for 72 h and images were taken at x20 or x40 
magnification. (B) The assay was repeated after 96 h with additional NucBlue nuclear stain (blue). EN2 has a 
granular distribution within the cytoplasm.
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Discussion
It is now generally accepted that a key part of tumor biology is the reactivation and re-tasking of developmental 
pathways and genes to support a malignant phenotype. EN2, a transcription factor that can be secreted from cells 
and taken up by others3, provides a particularly striking example of this phenomenon. In this study we have sort 
to elucidate the mechanisms that underlie EN2 protein secretion and uptake. Our findings indicate that EN2 pro-
tein can be secreted from cancer cells via microvesicles and that it can be taken up by other, non-EN2 expressing 
cells. This was restricted to PC3 cells, and was not observed in the other prostate cancer-derived cell lines tested, a 
finding that possibly reflects the very wide variation in the concentration of secretory vesicles found in the plasma 
of prostate cancer patients25. In addition to secretory vesicles, EN2 protein is present in the plasma membrane of 
cells, and although further work is needed to understand the exact mechanism of insertion and its relationship 
with the phospholipid bilayer, our findings indicate that part of the EN2 protein is exposed on the outside of the 
cell, and hence could potentially act as a target in antibody-directed therapy.
In addition to being taken up by other cancer cells, we found that EN2 can be taken up by cells derived from 
fibroblasts that would normally form part of the stroma surrounding tumors. This concurs with the findings of 
earlier studies11–15, but we have extended this to assess how it might influence the behavior of normal cells. We 
show that externally supplied EN2 protein can cause a specific, dose-dependent increase in MX2 gene expression 
in fibroblast cells. Furthermore, while neither MX2 protein nor RNA was detected in prostate tumors, or indeed 
in normal prostate cells in the absence of cancer, both are detected at high levels in ‘normal’ stromal cells adja-
cent to tumors. These findings indicate that EN2 secretion by prostate tumors can cause MX2 to be expressed by 
the surrounding stroma. MX2 is a dynamin-related GTPase that is primarily located at the cytoplasmic inter-
face of nuclear pores and has a role in nuclear transport and cell cycle regulation, as expression of a dominant 
negative (GTPase inactive) version blocks nuclear import and prevents G1/M transition26. Its primary cellular 
function seems to be the inhibition of the viral life cycle as it can block the assembly of multiple viruses27 includ-
ing the vesicular stomatitis virus28, and prevent the nuclear entry of HIV29. The relevance of EN2-induced MX2 
expression in cells adjacent to the tumor is unclear, although it could be advantageous for the tumor to prevent 
viral infection of stromal cells that would otherwise generate a localized immune response. To date there are no 
reported studies that directly support this hypothesis, although a single nucleotide polymorphism (SNP) in the 
MX2 gene has been found to be associated with a reduced overall risk of melanoma30.
















Figure 6. Exogenous EN2 protein induces the expression of MX2 in WPMY-1 cells. (A) Location of a putative 
EN2/PBX binding site in the genomic sequence of MX2. (B) MX2 expression in WMPY-1 cells treated with 
recombinant EN2 or actin protein. (C) Expression of MX2 and EN2 in normal prostate tissue (‘Normal’), 
prostate tumours and normal tissue adjacent to tumours (‘NAT’). Expression is shown relative to the house 
keeping gene GAPDH (x1000). Error bars represent the SEM for three independent experiments, *p < 0.05, 
**p < 0.01. (D) MX2 protein expression in prostate tumours. Immunohistochemical staining of a prostate 
tumour section (PCa) and normal prostate tissue (Normal). MX2 staining (brown) is present in the stroma 
surrounding tumour cells but not in normal prostate stroma. Scale bar: 80 μm.
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Conclusion
Taken together, our findings suggest that EN2 secretion and uptake represent a novel mechanism by which tum-
ors can influence the behavior of surrounding cells. EN2 can be secreted from cells via microvesicles that originate 
in the nucleus and also be inserted into the membrane, possibly through the same mechanism. These vesicles can 
be taken up by other cancer cells, and by stromal cells (although a different mechanism might also be involved). 
In the latter, EN2 drives expression of the MX2 gene, a key component of the innate defense against viral infection 
(Fig. 7), which in turn helps prevent a viral-mediated localized immune response that could indirectly expose the 
tumor to immune-mediated killing. Further study of the action of EN2 and the significance of MX2 expression in 
the stroma should help clarify the significance of this protective mechanism.
Data Availability
All data generated or analysed during this study are included in this published article [and its Supplementary 
Information file].
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